Logo Image
|Articles|December 9, 2014

TrialScope's Latest Version of PharmaCM Supports European Clinical Trial Results Reporting

TrialScope announced general availability of the latest release of the PharmaCM platform

TrialScope, the global leader in clinical trial transparency and compliance solutions, today announced general availability of the latest release of the PharmaCM platform (v.2.2) that automates and manages clinical trial results reporting via the European Medicines Agency’s European Clinical Trials Database (EudraCT).

The new EudraCT results reporting functionality is a first-to-market solution that enables clinical trial sponsors to convert results data formatted for US National Institutes of Health registry (www.clinicaltrials.gov) to the format required for EudraCT.  This approach reduces the data entry effort for EudraCT results by up to 85% and applies preconfigured workflows and audit trails to the complex process of disclosing clinical trial results to the European registry. The requirement to report trial summary results became mandatory for sponsors as of 21 July 2014.

Mike Forgash, CEO, TrialScope, commented, “The TrialScope team is working diligently to expand the PharmaCM platform. We are releasing the EudraCT functionality in time for clinical trial sponsors to prepare to meet looming health authority disclosure deadlines throughout 2015.”

Thomas Wicks, TrialScope COO, added, “The EudraCT results reporting capabilities support sponsor internal processes for preparation, review and approval of clinical trial results prior to disclosing on the EudraCT website. This model enables sponsors to ensure the quality and accuracy of the data before making it available for public consumption via EudraCT.”

To learn more about PharmaCM and TrialScope’s EudraCT results reporting functionality or to schedule a demonstration, please contact [email protected].

Related to this article

View more
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
Read more
What the Epilepsy Community Has Taught Us About Trial Feasibility
What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
Read more